Variation in prevalence of PD-L1 expression has also been reported in studies evaluating other tumor types, including NSCLC (25), gastric cancer (27–29), urothelial cancer (30), triple-negative breast cancer (31), and cervical carcinoma (32). This evidence concerns the gene CD274 and triple-negative breast carcinoma.